Clinical trials: Myeloma-Multiple
Multiple Myeloma, Neoplasms
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
This open-label, multi-center study will assess the efficacy and safety of vemurafenib in participants with BRAF V600 mutation-positive cancers (solid tumors and multiple myeloma, except melanoma and papillary thyroid cancer) and…
- Trial name
- NCT01524978
- Testing
- cetuximab, vemurafenib
- Where
- 34 sites in United States, China and 4 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of pomalidomide monotherapy in subjects with refractory or relapsed and refractory multiple myeloma who were enrolled in study CC-4047-MM-003 (NCT01311687) and…
- Trial name
- NCT01324947
- Testing
- pomalidomide
- Where
- 91 sites in Australia, Belgium and 13 more
- Volunteers
- 74 people
- Sponsor
- Celgene
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A phase 3, randomized, open-label, parallel-controlled, multi-center study comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in subjects with relapsed or refractory multiple myeloma who received…
- Trial name
- NCT03952091
- Testing
- TJ202, Lenalidomide and Dexamethasone, Lenalidomide and Dexamethasone
- Where
- 41 sites in China, Taiwan
- Volunteers
- 289 people
- Sponsor
- TJ Biopharma Co., Ltd.
Multiple Myeloma
A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma
This is a phase I, first in human, single arm, open label study that will assess safety, tolerability and clinical activity of FHND6091 when taken orally on a weekly dosing schedule by patients with relapsed and refractory…
- Trial name
- NCT05271682
- Testing
- FHND6091
- Where
- 6 sites in China
- Volunteers
- 40 people
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Multiple Myeloma
A Study of NINLARO® in Chinese Adults With Multiple Myeloma
The main aim of this study is to check side effects and results in adults with multiple myeloma after switching from a bortezomib/carfilzomib -based to an Ixazomib-based treatment.
- Trial name
- NCT05013190
- Testing
- No intervention
- Where
- 12 sites in China
- Volunteers
- 72 people
- Sponsor
- Takeda
B Cell Lymphomas, Multiple Myeloma
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
Subjects treated with an ACTR product may participate in this long-term follow-up study after the completion of the final scheduled visit in the parent clinical study or other investigational setting, such as compassionate use…
- Conditions
- B Cell Lymphomas, Multiple Myeloma, Solid Tumor, HER-2 Protein Overexpression
- Trial name
- NCT02840110
- Testing
- ACTR T Cell Product
- Where
- 16 sites in United States
- Volunteers
- 22 people
- Sponsor
- Cogent Biosciences, Inc.
Multiple Myeloma
Selinexor and Backbone Treatments of Multiple Myeloma Patients
This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma…
- Trial name
- STOMP (NCT02343042)
- Testing
- Selinexor, Dexamethasone, Lenalidomide
- Where
- 25 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Karyopharm Therapeutics Inc
Multiple Myeloma
Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma
This is a single patient protocol for TNB-383B in a subject with relapsed/refractory multiple myeloma (MM) who is not a candidate for treatment regimens known to provide clinical benefit in MM.
- Trial name
- NCT04453397
- Testing
- TNB-383B
- Where
- United States
- Sponsor
- TeneoOne Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma
Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
This study evaluates the safety and efficacy of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients with…
- Trial name
- NCT00322491
- Testing
- G-CSF Plus Plerixafor
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Myeloma, Non-Hodgkin Lymphoma
PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients
This is a phase II study to evaluate the efficacy and safety of TG-0054 combined with G-CSF in mobilizing hematopoietic stem cells in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.
- Conditions
- Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease
- Trial name
- NCT02104427
- Testing
- TG-0054 combined with G-CSF
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- GPCR Therapeutics, Inc.
Anemia of Chronic Disease
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer
This study is conducted to determine the safety, tolerability, and efficacy of NOX-H94 in patients with anemia of chronic disease (ACD).
- Trial name
- NCT01691040
- Testing
- NOX-H94
- Where
- 11 sites in Austria, Bulgaria and 1 more
- Volunteers
- 12 people
- Sponsor
- TME Pharma AG
Relapsed or Refractory Multiple Myeloma
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
This study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease.
- Trial name
- NCT06574568
- Testing
- YKST02
- Where
- 12 sites in China
- Volunteers
- 70 people
- Sponsor
- Excyte Biopharma Ltd
Multiple Myeloma
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
- Trial name
- MonumenTAL-2 (NCT05050097)
- Testing
- Talquetamab, Carfilzomib, Daratumumab SC
- Where
- 31 sites in United States, Australia and 4 more
- Volunteers
- 166 people
- Sponsor
- Janssen Research & Development, LLC
Fatigue, Multiple Myeloma
A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma
The purpose of this study is to evaluate the efficacy of armodafinil for the treatment of cancer-related fatigue in adult patients with multiple myeloma.
- Trial name
- NCT01160380
- Testing
- armodafinil
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Oncotherapeutics
Hematologic Malignancies
A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
The purpose of the study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (RRMM) at the recommended Phase 2 dose (RP2D) identified in Study 64007957MMY1001…
- Trial name
- NCT04696809
- Testing
- Teclistamab
- Where
- 15 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Janssen Pharmaceutical K.K.
Relapsed Refractory Multiple Myeloma (RRMM)
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that…
- Trial name
- LINKER-MM3 (NCT05730036)
- Testing
- Linvoseltamab, Elotuzumab, Pomalidomide
- Where
- 159 sites in United States, Australia and 16 more
- Volunteers
- 410 people
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
This was a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor…
- Trial name
- NCT04318327
- Testing
- PHE885
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals
B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors.
- Conditions
- B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT07239323
- Testing
- Invivo CAR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Myeloma, Multiple
CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma
This study is to determine the maximum tolerated dose(MTD), dose limiting toxicity(DLT), safety and pharmacokinetics(PK) profile of a single agent CKD-581 injection in Combination with Bortezomib and Dexamethasone in patients…
- Trial name
- NCT03051841
- Testing
- CKD-581
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Multiple Myeloma in Relapse, Multiple Myeloma Refractory
Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.
To Evaluate Safety and Efficacy of S103 for Treating Relapsed or Refractory Multiple Myeloma
- Trial name
- NCT07421856
- Testing
- Autologous BCMA-targeting CAR T cells
- Volunteers
- 24 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.